

## Temporary benefits added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Next Choice 0.75 mg Tablet (DIN 02364905), manufactured by Actavis Pharma Company, and Plan B 0.75 mg Tablet (DIN 02241674), manufactured by Teva Branded Pharmaceutical Products R&D Inc./Paladin Labs Inc., Plan B 1.5 mg Tablet (DIN 02293854), manufactured Teva Branded Pharmaceutical Products R&D Inc./Paladin Labs Inc., will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of **December 1, 2017**, all claims for Plan B 1.5 mg Tablet (DIN 02293854) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at [www.ab.bluecross.ca/providers/pharmacy-home.html](http://www.ab.bluecross.ca/providers/pharmacy-home.html).

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

Due to the unavailability of Pharixia 1.5 mg/ml Solution (DIN 02229777), manufactured by Pendopharm Inc., Odan-Benzylamine 1.5 mg/ml Solution (DIN 02463105), manufactured Odan Laboratories Ltd., will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of **December 5, 2017**, all claims for Odan-Benzylamine 1.5 mg/ml Solution (DIN 02463105) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at [www.ab.bluecross.ca/providers/pharmacy-home.html](http://www.ab.bluecross.ca/providers/pharmacy-home.html).

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics, and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

## Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage for Novo-Clobazam 10 mg Tablet (DIN 02238334) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping effective **January 5, 2018**.

### CLOBAZAM

#### 10 MG TABLET

00002238334	NOVO-CLOBAZAM	TEV	\$ 0.1152
00002244638	APO-CLOBAZAM	APX	\$ 0.2197

... continued from previous page

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage for Ratio-Lenoltec No. 3 Tablet (DIN 00653276) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping effective **January 8, 2018**.

#### CODEINE PHOSPHATE/ ACETAMINOPHEN/ CAFFEINE

##### 30 MG / 300 MG / 15 MG TABLET

00000653276	RATIO-LENOLTEC NO.3	TEV	\$ 0.0889
00002163926	TYLENOL NO. 3	JAI	\$ 0.1052

Alberta Blue Cross has been advised by Mylan Pharmaceuticals ULC that the shortage for Mylan-Buprenorphine Naloxone 2 mg/0.5 mg Sublingual Tablet (DIN 02408090) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping effective **January 8, 2018**.

#### BUPRENORPHINE HCL/ NALOXONE HYDROCHLORIDE DIHYDRATE

##### 2 MG / 0.5 MG SUBLINGUAL TABLET

00002408090	MYLAN-BUPRENORPHINE NALOXONE	MYP	\$ 1.3350
00002424851	PMS-BUPRENORPHINE/NALOXONE	PMS	\$ 1.3350
00002295695	SUBOXONE	IUK	\$ 2.6700

Alberta Blue Cross has been advised by Sandoz Canada Inc. that the shortage for Methotrexate (Preserved) 25 mg/ml Injection USP (DIN 02398427) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping effective **January 10, 2018**.

#### METHOTREXATE SODIUM

##### 25 MG / ML INJECTION

00002398427	METHOTREXATE (PRESERVED)	SDZ	\$ 4.4600
00002182777	METHOTREXATE SOD. (PRESERVED)	HSP	\$ 8.4472

#### When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit [www.ab.bluecross.ca/providers/pharmacy-home.php](http://www.ab.bluecross.ca/providers/pharmacy-home.php)



\*\*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. \*† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.713 2017/12

